Lung Cancer Hub | CarePedia Information Center

What Is Lung Cancer?

Types, mutations, and global epidemiology

2.2M

New diagnoses globally each year (WHO 2024)

1.8M

Annual deaths from lung cancer worldwide

80–85%

Of cases are Non-Small Cell (NSCLC)

50%+

Of NSCLC patients have a targetable driver mutation

Why lung cancer treatment has transformed: Until 2010, most advanced lung cancer patients received the same platinum-based chemotherapy. Today, oncologists first test for specific genetic mutations (EGFR, ALK, KRAS, ROS1, and others), and more than half of patients qualify for a precisely targeted drug that can outperform chemotherapy dramatically. This has roughly doubled 5-year survival rates in some subtypes from under 5% to 20-30% and beyond.

Main Types of Lung Cancer

Adenocarcinoma

The most common type (~40% of all lung cancers). Forms in mucus-producing cells, usually in the outer lung. Most common in non-smokers and women. Most likely to carry targetable mutations (EGFR, ALK, ROS1, KRAS).

NSCLCMost targetable

Squamous Cell Carcinoma

Arises from flat cells lining the airways, typically centrally near the bronchi. Strongly linked to smoking. Less likely than adenocarcinoma to carry EGFR/ALK mutations; immunotherapy plays a larger role.

NSCLC25–30% of cases

Small Cell Lung Cancer (SCLC)

Fast-growing, aggressive cancer almost exclusively in smokers. Spreads rapidly — over 70% of patients have distant metastases at diagnosis. Highly sensitive to chemotherapy initially, but recurrence is common. Immunotherapy (atezolizumab + chemo) is now first-line standard.

10–15% of casesAggressive growth

Large Cell Carcinoma

Can develop anywhere in the lung, grows quickly, and often presents late. The most aggressive NSCLC subtype with the poorest prognosis among non-small cell types. PD-L1 testing is important as immunotherapy may benefit some patients.

NSCLC10–15% of NSCLC

Key Genetic Mutations & Biomarkers

Before starting treatment, all advanced NSCLC patients should have comprehensive genomic profiling. The mutation found determines the treatment pathway.

Mutation	Frequency (NSCLC)	Key Drugs	Notes
EGFR	10–15% (higher in Asian patients)	Osimertinib (Tagrisso), Erlotinib, Gefitinib, Afatinib	Most common actionable mutation; exon 19 del + L858R most common
KRAS G12C	3–4% of NSCLC	Sotorasib (Lumakras), Adagrasib (Krazati)	First druggable KRAS variant; first approved 2021
ALK rearrangement	3–5%	Alectinib (Alecensa), Lorlatinib (Lorbrena), Crizotinib	Lorlatinib CROWN trial: median PFS not reached at 5 years
ROS1 rearrangement	1–2%	Entrectinib (Rozlytrek), Epotrectinib (Augtyro), Crizotinib	Excellent CNS penetration with newer agents
BRAF V600E	1–3%	Dabrafenib + Trametinib	Combination BRAF+MEK inhibition; 60–70% response rate
MET exon 14 skipping	3–4%	Capmatinib (Tabrecta), Tepotinib (Tepmetko)	More common in older patients and adenocarcinoma
RET rearrangement	1–2%	Selpercatinib (Retevmo)	70–80% response rate; superior to older multikinase inhibitors
HER2 mutation	2–4%	Trastuzumab deruxtecan (Enhertu)	ADC; FDA approval expected 2025 for first-line HER2-mutant NSCLC
NTRK fusion	<1%	Larotrectinib (Vitrakvi), Entrectinib	Pan-cancer target; 70%+ response rate
PD-L1 expression	~30% high (≥50%)	Pembrolizumab (Keytruda) monotherapy	Not a mutation, but key biomarker for immunotherapy selection

Epidemiology & Risk Factors

Global burden: Lung cancer is the most common cancer worldwide and the #1 cause of cancer death in both men and women. About 2.2 million new cases are diagnosed annually, with 1.8 million deaths.

Survival improving: The 5-year survival rate in the US has risen from ~17% (2010) to ~28% (2024), driven primarily by targeted therapies, immunotherapy, and earlier detection. Stage I survival exceeds 90% with surgery.

Main risk factors:

Smoking — responsible for ~85% of lung cancers; risk is dose-dependent
Secondhand smoke — 20–30% increased risk in non-smokers exposed
Radon gas — second leading cause of lung cancer; colorless/odorless radioactive gas in homes
Asbestos exposure — especially construction and industrial workers
Air pollution — PM2.5 and industrial emissions (classified as carcinogen by IARC)
Occupational hazards — arsenic, chromium, nickel, beryllium, silica
Family history — first-degree relative with lung cancer modestly increases risk

Never-smoker lung cancer: ~15–20% of lung cancer patients never smoked. These cases are more likely to carry targetable mutations (EGFR, ALK) and tend to be adenocarcinomas.

Symptoms & Diagnosis

Warning signs, staging, and diagnostic workup

Early lung cancer is often silent. Most patients have no symptoms until the disease is at an advanced stage. This is why screening high-risk individuals with low-dose CT is so important (see the Screening section).

Common Symptoms

Respiratory Symptoms

Persistent cough that worsens or doesn't resolve
Coughing up blood (hemoptysis) — requires urgent evaluation
Shortness of breath (dyspnea), especially with exertion
Wheezing or new onset of hoarseness
Recurrent pneumonia or bronchitis
Chest pain, especially when breathing deeply, coughing, or laughing

Systemic & Advanced Symptoms

Unexplained weight loss and loss of appetite
Fatigue and weakness
Bone pain (shoulder, back) — possible bone metastasis
Headache, dizziness — possible brain metastasis
Swelling of face/arms — superior vena cava syndrome
Jaundice — possible liver involvement

Paraneoplastic Syndromes

Rare hormonal or neurological syndromes caused by cancer-secreted substances, not metastasis. More common with SCLC.

SIADH (sodium imbalance, confusion)
Cushing's syndrome (ACTH production)
Hypercalcemia (squamous cell carcinoma)
Lambert-Eaton syndrome (muscle weakness)

Diagnostic Workup

Step 1 — Imaging

Chest X-ray (initial), followed by CT scan of chest, abdomen, and pelvis (standard). CT defines tumor size, location, lymph node involvement, and distant spread. PET-CT integrates metabolic activity to detect metastases more accurately.

Step 2 — Tissue Biopsy

Required to confirm diagnosis and obtain tissue for molecular testing. Methods include: CT-guided needle biopsy, bronchoscopy with EBUS (endobronchial ultrasound), VATS (video-assisted thoracoscopic surgery) for peripheral lesions, or mediastinoscopy for lymph nodes.

Step 3 — Molecular & Biomarker Testing

All advanced NSCLC patients should receive comprehensive genomic profiling. Tests cover: EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK, HER2 mutations AND PD-L1 expression. Liquid biopsy (ctDNA blood test) is an alternative when tissue is insufficient — FDA-approved comprehensive liquid biopsy panels now available (2024).

Step 4 — Brain MRI & Bone Scan

Brain MRI is standard for all stage III-IV NSCLC and SCLC (lung cancer has high brain metastasis risk). Bone scan or PET identifies bone metastases.

Step 5 — Staging (TNM System)

Staging uses the TNM system: T (tumor size/invasion), N (lymph node involvement), M (distant metastasis). Stages I–II are potentially curable with surgery. Stage III is locally advanced. Stage IV is metastatic but increasingly treatable.

Staging Guide: What Each Stage Means

Stage	Description	5-Year Survival (NSCLC)	Primary Treatment
Stage I	Tumor confined to lung, no lymph node spread	70–92%	Surgery (lobectomy/VATS), SBRT if inoperable
Stage II	Tumor with nearby lymph node involvement	40–60%	Surgery + adjuvant chemotherapy ± immunotherapy
Stage III	Locally advanced; mediastinal nodes involved	10–35%	Concurrent chemoradiation ± durvalumab consolidation
Stage IV	Metastatic (distant organs affected)	5–20% (improving)	Systemic therapy: targeted agents, immunotherapy, or chemo

Treatments & Therapies

Surgery, chemotherapy, targeted therapy, immunotherapy, and radiation

The #1 rule in lung cancer treatment (2024): Know your mutation before starting therapy. The treatment for EGFR-mutant lung cancer is completely different from ALK-positive, KRAS-mutant, or PD-L1-high disease. Comprehensive genomic profiling first saves lives.

Surgical Options

Lobectomy — removal of one lobe; gold standard for Stage I–II NSCLC. 5-year survival 70–90% for Stage IA.
Segmentectomy / Wedge resection — less tissue removed; for small tumors or limited lung function.
Pneumonectomy — removal of entire lung; reserved for central tumors.
VATS (Video-Assisted Thoracoscopic Surgery) — minimally invasive; less pain, faster recovery, equivalent oncologic outcomes to open surgery.
Robotic surgery — increasingly used; excellent for complex resections with faster recovery.

Who Qualifies for Surgery?

Surgery is the primary curative option for Stage I and II NSCLC and selected Stage IIIA cases. Requirements:

Adequate lung function (pulmonary function tests)
No distant metastases
Tumor technically resectable
Patient able to tolerate anesthesia

Post-surgery: Adjuvant chemotherapy (carboplatin/cisplatin + pemetrexed/vinorelbine) is standard for Stage IB–III. Adjuvant osimertinib for EGFR-mutant and adjuvant pembrolizumab/atezolizumab are approved and improve survival.

Standard Regimens

NSCLC Nonsquamous: Pemetrexed (Alimta) + Carboplatin or Cisplatin — first-line; pemetrexed maintenance for stable/responding disease
NSCLC Squamous: Gemcitabine or Paclitaxel (Taxol) + Carboplatin or Cisplatin
SCLC: Etoposide + Carboplatin or Cisplatin (EP regimen) — often combined with atezolizumab immunotherapy; highly effective initially
Nab-paclitaxel (Abraxane) + Carboplatin — alternative for squamous NSCLC

Second-Line Chemotherapy

Docetaxel (Taxotere) — most common second-line after platinum failure
Docetaxel + Ramucirumab (Cyramza) — anti-VEGFR2; modest OS benefit
Docetaxel + Nintedanib (Vargatef) — approved in Europe for adenocarcinoma
Single-agent vinorelbine (Navelbine), gemcitabine in selected patients

Note: Chemotherapy is typically not recommended when a targetable driver mutation is present — targeted drugs significantly outperform chemotherapy in those cases.

EGFR Inhibitors

Drug (Brand)	Generation	Dose	Key Data
Osimertinib (Tagrisso)	3rd gen	80 mg daily	FLAURA trial: PFS 18.9 vs 10.2 months vs erlotinib. Preferred first-line for all common EGFR mutations.
Amivantamab + Lazertinib	Bispecific + TKI	IV + oral	MARIPOSA trial 2024: superior PFS vs osimertinib alone. FDA approved August 2024.
Erlotinib (Tarceva)	1st gen	150 mg daily	Still used; alternative when osimertinib not accessible.
Gefitinib (Iressa)	1st gen	250 mg daily	Alternative to erlotinib; similar efficacy.
Afatinib (Gilotrif)	2nd gen	40 mg daily	Covers uncommon EGFR mutations well.

ALK Inhibitors

Drug (Brand)	Generation	Key Data
Lorlatinib (Lorbrena)	3rd gen	CROWN 5-year data 2024: median PFS NOT REACHED. Standard first-line ALK+.
Alectinib (Alecensa)	2nd gen	ALEX trial: PFS 34.8 vs 10.9 months vs crizotinib. Excellent brain penetration.
Brigatinib (Alunbrig)	2nd gen	ALTA-1L: PFS 24 months. Good CNS efficacy.
Crizotinib (Xalkori)	1st gen	Also covers ROS1; largely replaced by newer agents.

KRAS G12C Inhibitors

Sotorasib (Lumakras)

First KRAS-targeted drug approved (FDA May 2021). Oral, 960 mg daily. CodeBreaK 200: ORR 36%, median PFS 6.8 months. Second-line KRAS G12C NSCLC.

Adagrasib (Krazati)

FDA approval December 2022. Oral, 600 mg twice daily. KRYSTAL-1: ORR 43%. Better combination potential with immunotherapy (no mandatory washout).

Immunotherapy works by blocking the PD-1/PD-L1 checkpoint, allowing T cells to recognize and destroy cancer cells. Works best when PD-L1 expression is high (≥50%) and there is no targetable driver mutation (EGFR/ALK).

Drug (Brand)	Target	Approved Indication	Key Data
Pembrolizumab (Keytruda)	Anti-PD-1	First-line PD-L1 ≥50%; all stages; adjuvant post-surgery (2023)	KEYNOTE-024: OS 15.2 vs 8.9 months vs chemo in PD-L1≥50%
Nivolumab (Opdivo)	Anti-PD-1	Previously treated NSCLC; neoadjuvant + adjuvant (CheckMate 816)	Neoadjuvant pCR 24% with + chemo
Atezolizumab (Tecentriq)	Anti-PD-L1	NSCLC + chemo; SCLC first-line + chemo; adjuvant post-surgery	IMpower150 OS 19.2 months
Durvalumab (Imfinzi)	Anti-PD-L1	Stage III NSCLC after chemoradiation; SCLC first-line (2024)	PACIFIC: 5-year OS 42.9% vs 33.4% placebo

Pembrolizumab + Chemo (KEYNOTE-189)

Nonsquamous NSCLC: pembro + pemetrexed + carboplatin. Median OS 22 vs 10.7 months vs chemo alone. Standard first-line for nonsquamous NSCLC without driver mutations.

Nivolumab + Ipilimumab (CheckMate 9LA)

Squamous NSCLC. Dual checkpoint blockade (PD-1 + CTLA-4). OS 15.6 vs 10.9 months vs chemo alone. Broader immune activation.

SBRT

Stereotactic Body Radiation Therapy. High-dose, precise radiation in 3–5 fractions. Curative for Stage I peripheral NSCLC in inoperable patients. Local control: 90%+ at 5 years.

Chemoradiation (Stage III)

Concurrent platinum-based chemo + IMRT for locally advanced Stage III. Standard dose: 60–66 Gy. Followed by durvalumab consolidation (PACIFIC trial: 5-year OS 42.9%).

Brain & Palliative Radiation

Stereotactic radiosurgery (SRS) for 1–4 brain metastases — equal local control with less cognitive toxicity than whole-brain radiation. Palliative radiation for painful bone metastases: highly effective in 2–5 fractions.

Enhertu (Trastuzumab Deruxtecan)

HER2-targeting ADC. DESTINY-Lung04: first-line HER2-mutant NSCLC — 60%+ response rates vs standard chemo. FDA approval expected 2025.

Dato-DXd (Datopotamab Deruxtecan)

TROP-2 targeting ADC. TROPION-Lung01: OS benefit in previously treated NSCLC. FDA under priority review 2024-2025. Applicable regardless of mutation status.

Personalized Vaccines

Autogene Cevumeran + Pembrolizumab in post-neoadjuvant setting for resectable NSCLC. Early data: 40–50% recurrence reduction. Multiple Phase 3 trials active 2025.

TIL Therapy

Tumor-infiltrating lymphocyte therapy. MSK Phase 2 showing efficacy in immunotherapy-refractory NSCLC AND SCLC (first-ever in SCLC). 40–60% early response rates (2024).

Clinical Trials

Active trials 2024-2025 — find your next option

Clinical trials are not a last resort. Many oncologists recommend considering trials at every stage — especially at Stage IV diagnosis, first relapse, or when standard options are limited. Participation gives access to next-generation drugs 2–5 years before approval.

DESTINY-Lung04 (Phase 3)

Enhertu vs chemo + pembro for first-line HER2-mutant NSCLC. Daiichi Sankyo / AstraZeneca. NCT05048797. Active enrollment 2024-2025.

Beamion LUNG-2 (Phase 3)

Zongertinib (HER2 TKI) vs KEYNOTE-189 regimen for HER2-mutant NSCLC. Boehringer Ingelheim. NCT06151574. Recruitment 2024-2025.

LATIFY (Phase 3)

Ceralasertib + Durvalumab vs docetaxel in previously treated advanced NSCLC. AstraZeneca. ASCO/ESMO data 2025.

MSK TIL Therapy (Phase 2)

TIL therapy for immunotherapy-refractory NSCLC and SCLC. Memorial Sloan Kettering. Active enrollment 2024-2025.

KRAS G12D/G12V Trials (Previously Undruggable Mutations)

KRAS G12D and G12V represent the majority of KRAS mutations (~25% of all NSCLC) — previously considered completely undruggable. Multiple combination trials now open in 2024-2025:

RMC-6236 (RAS(ON) inhibitor) — covers multiple KRAS variants including G12D/G12V; Phase 1-2 trials showing promising early data
MRTX-1133 (KRAS G12D selective) — Phase 1 recruiting; first dedicated G12D inhibitor in lung cancer
KRAS inhibitor + MEK inhibitor + Immunotherapy combinations — multiple sponsors, Phase 2-3

Expected approvals for KRAS G12D/G12V agents: 2026-2027 if current trials confirm Phase 1 results.

Neoadjuvant / Adjuvant Immunotherapy Trials

Intismeran (personalized vaccine) + Pembrolizumab — post-neoadjuvant for resectable NSCLC with incomplete response; Phase 3
LAURA trial (osimertinib Stage III) — already approved July 2024; PFS 39.1 vs 5.6 months vs placebo. Long-term follow-up ongoing.
ADAURA extension studies — long-term follow-up of adjuvant osimertinib (Stage IB-IIIA EGFR-mutant)

ADC Trials (Antibody-Drug Conjugates)

TROPION-Lung08 — Dato-DXd + pembrolizumab vs chemo + pembro for first-line NSCLC without driver mutations; Phase 3
DESTINY-Lung04 — Enhertu for HER2-mutant NSCLC first-line (see above)
LUMINOSITY expansion — Telisotuzumab vedotin (c-Met ADC) for MET-overexpressing NSCLC; data at ASCO 2024

→

How to Find the Right Clinical Trial

Visit ClinicalTrials.gov and search "lung cancer" + your mutation type + "phase 2" or "phase 3". Your oncologist can also check NCI-matched trials through major cancer center registries (Mayo Clinic, MSKCC, MD Anderson, Cleveland Clinic). Ask specifically: "Is there a trial I qualify for?" at every visit.

Latest Research (2024-2025)

Breakthroughs, new approvals, and science at the frontier

Lorlatinib — CROWN 5-Year Data

NEJM 2024: Median PFS for ALK+ NSCLC on lorlatinib was NOT REACHED after 5 years. First agent in advanced NSCLC achieving this milestone — a paradigm-shifting result for ALK-positive patients.

Amivantamab + Lazertinib (MARIPOSA)

MARIPOSA trial 2024: superior PFS vs osimertinib alone for first-line EGFR-mutant NSCLC. FDA approved August 2024. Bispecific antibody (EGFR+MET) + 3rd-gen TKI combination.

Osimertinib + LAURA (Stage III)

LAURA trial 2024: osimertinib after chemoradiation for EGFR-mutant Stage III. PFS 39.1 vs 5.6 months vs placebo. FDA approved July 2024. Transforms unresectable Stage III management.

TIL Therapy in SCLC

2024 breakthrough: TIL therapy showed efficacy in small cell lung cancer for the first time. Opens a new avenue for this aggressive subtype. MSK Phase 2 data showed 40–60% response rates in early cohorts.

Liquid Biopsy Revolution

ctDNA blood tests now FDA-approved for comprehensive genomic profiling — allowing mutation testing without tissue biopsy.

Detection lead time: identifies recurrence 2–3 months before imaging
Sensitivity: 70–90% for actionable mutations
Serial monitoring tracks resistance mutations in real-time
Guides therapy switches before clinical progression

AI in Detection

Deep learning integrated with low-dose CT screening programs achieving >95% sensitivity for nodule detection with significantly reduced false-positive rates (2024-2025).

Enables higher-throughput national screening
Radiomic signatures predicting immunotherapy response
Combined imaging + ctDNA dual-modality screening in trials

Immunotherapy in Curative Settings

Major 2023-2024 paradigm shift — immunotherapy approved for post-surgery use:

Pembrolizumab adjuvant: approved 2023 (KEYNOTE-091)
Atezolizumab adjuvant: approved 2023 (IMpower010)
Nivolumab neoadjuvant + adjuvant: approved 2022
Expected 10-15% absolute survival improvement at 5 years

Emerging Biomarkers Beyond PD-L1

Tumor Mutational Burden (TMB): High TMB (>10 mut/Mb) predicts better response to checkpoint inhibitors. Nivolumab + ipilimumab in TMB-H tumors shows improved OS.
STK11/KEAP1 mutations: Associated with reduced immunotherapy benefit even in PD-L1 high tumors — guide toward chemo-immunotherapy combinations.
Microbiome composition: Gut microbiome diversity linked to immunotherapy response. Antibiotic use within 30 days of checkpoint inhibitor start reduces efficacy.
Immune gene signatures: T cell-inflamed gene expression profiles predicting immunotherapy response beyond PD-L1.

Resistance Mechanisms & How to Overcome Them

EGFR resistance (osimertinib): C797S mutation, amplification, histologic transformation. Next options: allosteric EGFR inhibitors + amivantamab combinations — multiple trials active.
ALK resistance: Secondary mutations; lorlatinib active against most alectinib/brigatinib resistance mutations.
Immunotherapy resistance: Low TILs, microbiome dysbiosis. Emerging TIGIT/LAG-3 combination trials to overcome "cold" tumors.
Liquid biopsy for resistance: ctDNA identifies resistance mutations 2–3 months before imaging — enables rapid therapy switch.

Early Detection & Screening

Low-dose CT screening guidelines and who qualifies

Screening saves lives. The National Lung Screening Trial (NLST) demonstrated that annual low-dose CT (LDCT) screening reduces lung cancer mortality by 20% in high-risk individuals. Stage I detection rates increase from ~15% (symptomatic) to 50–60% (screening).

USPSTF Criteria (2021 Update)

The US Preventive Services Task Force recommends annual LDCT screening for individuals meeting ALL criteria:

Age: 50–80 years old
Smoking history: 20+ pack-years (packs/day × years smoked)
Current smoker OR quit within the past 15 years
No symptoms suggestive of lung cancer

Updated 2021 Age lowered from 55 to 50; pack-years lowered from 30 to 20 — increases eligible population by ~50%.

Important Limitations

Screening is for high-risk individuals only — not for the general population
False positives are common (up to 25%) — most require only follow-up CT, not invasive biopsy
Smoking cessation counseling must accompany screening
Results should be discussed with a pulmonologist or thoracic specialist
Screening does not eliminate the need to see a doctor for symptoms

What LDCT Detects

Low-dose CT (LDCT) — radiation dose 1.5 mSv vs 7 mSv standard CT — detects:

Pulmonary nodules (small spots in the lung)
Most nodules are benign (infection, scar tissue)
Suspicious nodules are categorized (Lung-RADS score 1–4)
Volumetric analysis (2024) more reproducible than diameter measurement

Lung-RADS Score — What It Means

Lung-RADS Score	Meaning	Recommended Action
1 — Negative	No significant nodules	Continue annual screening
2 — Benign	Nodule with very low malignancy risk (<1%)	Continue annual screening
3 — Probably benign	Nodule with low risk (~1–2%)	6-month follow-up CT
4A — Suspicious	Moderate risk (~5–15%)	3-month follow-up CT or PET-CT
4B — Very suspicious	High risk (>15%)	Tissue sampling (biopsy) recommended
4X — Very high risk	Additional features suggesting malignancy	Immediate clinical evaluation and biopsy

Screening Programs Around the World

United States: USPSTF guidelines (2021) — annual LDCT for ages 50–80, 20+ pack-years. Medicare covers screening for qualifying patients.
United Kingdom: NHS Targeted Lung Health Check program expanding nationally — LDCT for ages 55–74, current or former smokers.
European Union: EU Cancer Beating Plan recommends implementing national screening programs; currently rolling out in multiple countries.
Canada: Several provinces piloting or implementing screening programs modeled on USPSTF criteria.
Australia: Lung cancer screening feasibility studies ongoing; national program expected 2025-2026.

Lifestyle & Prevention

Risk reduction, smoking cessation, and living well during treatment

Quit Smoking — #1 Priority

Quitting smoking at any age reduces lung cancer risk — and even after diagnosis, quitting improves treatment outcomes, reduces complications, and may improve immunotherapy response.

Varenicline (Chantix): Most effective pharmacotherapy — 50–70% quit rate. Discuss with doctor.
Bupropion (Zyban): 40–50% quit rate. Antidepressant mechanism.
NRT (patches, gum, lozenges): Over-the-counter; use combination for best results.
Behavioral counseling + medication: Combination achieves highest success rates.

Radon Testing — Your Home

Radon is the second leading cause of lung cancer — a colorless, odorless radioactive gas. Smoking + radon = multiplicative risk.

Test your home with an affordable radon kit (available at hardware stores)
Action level: >4 pCi/L — requires mitigation system
Mitigation: soil depressurization, sealing cracks, improved ventilation
Cost: typically $800–2,500 USD for mitigation system

Exercise During Treatment

Physical activity during and after lung cancer treatment improves quality of life, reduces fatigue, and may improve survival outcomes:

Aerobic exercise: 30 min moderate activity 3–5×/week
Resistance training: 2×/week to preserve muscle mass (sarcopenia worsens outcomes)
Pulmonary rehab: evidence-based for post-surgery patients — improves exercise capacity and lung function
Even short walks improve fatigue and mood

Nutrition Guidelines

Malnutrition is common in lung cancer and worsens treatment tolerance. Evidence-based recommendations:

Protein: 1.2–1.5 g/kg/day — preserves muscle mass during chemotherapy
Anti-inflammatory diet: Mediterranean pattern — vegetables, fish, olive oil, whole grains
Avoid supplements without oncologist approval — some antioxidants may interfere with radiation/chemotherapy
Register with a dietitian specializing in oncology if losing weight

Air Quality, Occupation, and Other Risk Reduction

Air pollution: IARC classifies outdoor air pollution (PM2.5, PM10) as a Group 1 carcinogen. Use air quality monitoring apps; avoid outdoor activity on high-pollution days. Use HEPA filters indoors.
Occupational exposures: Asbestos, arsenic, chromium, nickel, beryllium workers should follow all protective equipment guidelines. If you worked in construction, mining, or certain manufacturing pre-1980, discuss your history with your doctor.
Secondhand smoke: Even brief exposure increases risk. Ensure your home and car are smoke-free.
E-cigarettes/vaping: Long-term lung cancer risk unknown but associated with lung inflammation. Not proven safe or an effective cessation tool.

Psychological Approach

Mental health, coping strategies, and support for patients and caregivers

Up to 40–50% of lung cancer patients experience clinically significant anxiety or depression. Mental health treatment is not separate from cancer care — it directly affects treatment adherence, quality of life, and potentially outcomes. Ask your care team for a referral to a psycho-oncologist.

Evidence-Based Psychological Interventions

Cognitive Behavioral Therapy (CBT): Most evidence-based for cancer-related anxiety and depression. Targets distorted thinking patterns. Available individually or in groups.
Acceptance and Commitment Therapy (ACT): Helps patients accept uncertainty and live with values-based goals despite illness.
Mindfulness-Based Stress Reduction (MBSR): Reduces cancer-related distress, improves sleep quality, may improve immune function.
Supportive-Expressive Group Therapy: Weekly groups — reduces isolation, provides practical coping strategies.

Warning Signs to Report

Seek psychological support immediately if experiencing:

Persistent sadness, hopelessness, or feeling like a burden
Inability to make treatment decisions due to anxiety
Social withdrawal and loss of interest in all activities
Significant sleep disturbance lasting more than 2 weeks
Any thoughts of self-harm or suicide
Caregiver burnout with inability to continue care responsibilities

For Caregivers

Caregiver burden is significant — up to 50% of lung cancer caregivers develop anxiety or depression themselves:

Seek your own individual counseling — you need support too
Use respite care services to prevent burnout
Join caregiver-specific support groups (LUNGevity CareLine, GO2 Foundation)
Set realistic expectations — you cannot "fix" the situation, but you can "be there"
Monitor your own physical health — caregivers often neglect their own needs

Navigating Uncertainty — Coping with Advanced Disease

1

Focus on what you can control

Treatment decisions, lifestyle choices, relationships, and how you spend your time. The future is uncertain for everyone — professional support helps shift focus to the present.

2

Palliative care is not end-of-life care

Palliative care specialists manage symptoms (pain, breathlessness, fatigue, nausea) at any stage of treatment. Studies show patients who receive early palliative care alongside treatment actually live longer with better quality of life (Temel et al., NEJM 2010).

3

Advance care planning

Discussing your values and preferences in advance — not as giving up, but as ensuring your wishes are honored. Advance directives and healthcare proxy designations give you control and reduce family stress.

4

Financial and practical support

Cancer treatment is expensive. Many pharmaceutical companies offer patient assistance programs for targeted therapy drugs. Social workers at major cancer centers can connect you with local resources, transportation assistance, and financial counseling.

Real Stories & Advocacy

Patients, advocates, and communities making a difference

"I was told I had three to six months. That was six years ago. Turns out I was EGFR-positive and didn't know it. Osimertinib changed everything. Testing matters — advocate for comprehensive genomic profiling."

— Patient advocate, ALK+ lung cancer, diagnosed Stage IV, now 7 years post-diagnosis

"Nobody tells you that 20% of lung cancer patients never smoked. I was 38, fit, a runner — and had advanced adenocarcinoma. The stigma of lung cancer nearly kept me from talking about it. We need to change that conversation."

— Never-smoker lung cancer patient, stage IV adenocarcinoma with ROS1 rearrangement

"The CROWN trial data gave me hope I didn't know I could have. Lorlatinib's median PFS hasn't been reached. I'm two years in and still stable. The science is catching up to us."

— ALK-positive NSCLC patient, treated at a major cancer center, participating in a patient advisory board

Organizations Making a Difference

LUNGevity Foundation

The largest private funder of lung cancer research in the US. Provides peer-to-peer support through the CareLine, clinical trial matching, and caregiver resources. lungevity.org

GO2 Foundation for Lung Cancer

Patient advocacy, education, and research funding focused on lung cancer survivorship. Offers free patient support services and a clinical trial matching tool. go2foundation.org

IASLC (International Association)

The International Association for the Study of Lung Cancer — the world's leading professional organization for lung cancer research. Funds research and develops treatment guidelines. iaslc.org

Resources & Links

International organizations, medical centers, apps, and support

Apps & Online Resources

CancerCare

Free professional support services: counseling, support groups, financial assistance, and educational resources for lung cancer patients and families. cancercare.org

LUNGevity Lung Cancer Guides

Interactive treatment guides, mutation-specific information, and clinical trial matching tool for patients. Available at lungevity.org/support.

Understanding Lung Cancer

Navigate the Portal